Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D McKee

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|February 21, 2003
CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cellJeffrey J Roszkowski, David C Yu, Mark P Rubinstein, et al.
The Journal of Investigative Dermatology|August 7, 2009
Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentationVidhya Hariharan, Jared Klarquist, Mary J Reust, et al.
Hepatology (Baltimore, Md.)|April 22, 2006
Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognitionGlenda G Callender, Hugo R Rosen, Jeffrey J Roszkowski, et al.
Gynecologic Oncology|January 21, 2018
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignanciesHeidi J Gray, Katherine Bell-McGuinn, Gini F Fleming, et al.
The Journal of Laboratory and Clinical Medicine|March 2, 2002
Effects of interleukin 2 therapy on lymphocyte magnesium levelsMark D McKee, Stacey A Cecco, Julie E Niemela, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2014
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)Hidehito Horinouchi, Noboru Yamamoto, Hiroshi Nokihara, et al.
The American Journal of Pathology|November 7, 2009
Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cellsJared Klarquist, Allison Barfuss, Sridhar Kandala, et al.
Clinical Colorectal Cancer|July 29, 2014
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancerBert H O'Neil, Calin Cainap, Eric Van Cutsem, et al.
Lung Cancer (Amsterdam, Netherlands)|October 2, 2015
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanibEvelyn M McKeegan, Peter J Ansell, Gerard Davis, et al.
JAMA Surgery|January 9, 2020
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical TrialMehra Golshan, Sibylle Loibl, Stephanie M Wong, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Journal of Immunology (Baltimore, Md. : 1950)|February 21, 2003
CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cellJeffrey J Roszkowski, David C Yu, Mark P Rubinstein, et al.
The Journal of Investigative Dermatology|August 7, 2009
Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentationVidhya Hariharan, Jared Klarquist, Mary J Reust, et al.
Hepatology (Baltimore, Md.)|April 22, 2006
Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognitionGlenda G Callender, Hugo R Rosen, Jeffrey J Roszkowski, et al.
Gynecologic Oncology|January 21, 2018
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignanciesHeidi J Gray, Katherine Bell-McGuinn, Gini F Fleming, et al.
The Journal of Laboratory and Clinical Medicine|March 2, 2002
Effects of interleukin 2 therapy on lymphocyte magnesium levelsMark D McKee, Stacey A Cecco, Julie E Niemela, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2014
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)Hidehito Horinouchi, Noboru Yamamoto, Hiroshi Nokihara, et al.
The American Journal of Pathology|November 7, 2009
Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cellsJared Klarquist, Allison Barfuss, Sridhar Kandala, et al.
Clinical Colorectal Cancer|July 29, 2014
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancerBert H O'Neil, Calin Cainap, Eric Van Cutsem, et al.
Lung Cancer (Amsterdam, Netherlands)|October 2, 2015
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanibEvelyn M McKeegan, Peter J Ansell, Gerard Davis, et al.
JAMA Surgery|January 9, 2020
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical TrialMehra Golshan, Sibylle Loibl, Stephanie M Wong, et al.
Pageof 3